Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Common Equity: 2017-2024

Historic Common Equity for Bicycle Therapeutics (BCYC) over the last 8 years, with Dec 2024 value amounting to $793.1 million.

  • Bicycle Therapeutics' Common Equity fell 25.58% to $618.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $618.5 million, marking a year-over-year decrease of 25.58%. This contributed to the annual value of $793.1 million for FY2024, which is 113.80% up from last year.
  • Latest data reveals that Bicycle Therapeutics reported Common Equity of $793.1 million as of FY2024, which was up 113.80% from $370.9 million recorded in FY2023.
  • In the past 5 years, Bicycle Therapeutics' Common Equity registered a high of $793.1 million during FY2024, and its lowest value of $95.5 million during FY2020.
  • In the last 3 years, Bicycle Therapeutics' Common Equity had a median value of $370.9 million in 2023 and averaged $478.3 million.
  • Per our database at Business Quant, Bicycle Therapeutics' Common Equity spiked by 262.72% in 2021 and then dropped by 21.80% in 2022.
  • Bicycle Therapeutics' Common Equity (Yearly) stood at $95.5 million in 2020, then spiked by 262.72% to $346.3 million in 2021, then dropped by 21.80% to $270.8 million in 2022, then spiked by 36.98% to $370.9 million in 2023, then soared by 113.80% to $793.1 million in 2024.